5 completed, 1 terminated. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow BI 1819479: new trials by email Literature Review of BI 1819479 trials Research Report on BI 1819479
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test How BI 1819479 is Taken up and Processed by the Body [14C]BI 1819479, BI 1819479, BI 1819479 (C-14) - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 7 | 2025-08-04 | 2026-09-30 |
| A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) BI 1819479, Placebo matching BI 1819479 - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Boehringer Ingelheim | 322 | 2024-09-05 | 2026-07-27 |
| A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood BI 1819479, Esomeprazole - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2022-10-18 | 2023-01-26 |
| A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated BI 1819479, Matching placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2022-08-03 | 2023-04-05 |
| A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 BI 1819479, BI matching placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 62 | 2022-07-20 | 2023-08-14 |
| A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food BI 1819479, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 66 | 2021-05-26 | 2022-05-04 |
Idiopathic Pulmonary Fibrosis (1)
Germany (4) · Japan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Greece (1)
2023 (1)